Integrated Biopharma Inc (INBP) Stock Price & Analysis
Integrated Biopharma Inc (INBP) fell 9.11% to USD 0.17 as of June 10, 2026 at 07:41 UTC, according to Nexqual real-time market data.
INBP last closed at USD 0.19; the session ranged USD 0.17–0.18 on volume of 8,140 shares. Market capitalization is $5.36M, with a 52-week range of USD 0.17–0.42 (OQX). Source: Nexqual, June 10, 2026 at 07:41 UTC.
Key Statistics (as of June 10, 2026 at 07:41 UTC)
| Price | USD 0.17 |
|---|---|
| Change | ▼ 9.11% (down) |
| Previous Close | USD 0.19 |
| Open | USD 0.18 |
| Day Range | USD 0.17 – 0.18 |
| 52-Week Range | USD 0.17 – 0.42 |
| Volume | 8,140 shares |
| Market Cap | $5.36M |
| Exchange | OQX |
Technical Analysis (INBP)
Nexqual's technical model rates INBP "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:41 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.63 (neutral) |
| vs SMA50 | Below (USD 0.24) |
| MACD | -0.02 (negative) |
Analyst Ratings (INBP)
Wall Street analysts rate INBP "None", per Nexqual as of June 10, 2026 at 07:41 UTC.
| Consensus Rating | None |
|---|
Earnings (INBP)
Source: Nexqual, June 10, 2026 at 07:41 UTC.
Financials & Fundamentals (INBP)
| Total Revenue | $48.25M |
|---|---|
| Revenue Growth (YoY) | -27.50% |
| Gross Margin | +4.64% |
| Operating Margin | -10.73% |
| Profit Margin | -3.43% |
| ROE | -8.40% |
| Debt / Equity | 17.63 |
| Current Ratio | 3.25 |
| Total Cash | $5.83M |
| Total Debt | $3.35M |
| Free Cash Flow | $4.17M |
Source: Nexqual, June 10, 2026 at 07:41 UTC.
Financial Health Score (INBP)
Nexqual rates Integrated Biopharma Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:41 UTC.
| Growth | Critical — Revenue -28% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $6M cash vs $3M debt, net cash position |
| Cash Flow | Solid — FCF $4M, 9% margin |
| Efficiency | Critical — ROE -8%, ROA -3.0% |
Ownership (INBP)
| Insider Ownership | +68.43% |
|---|---|
| Institutional Ownership | +0.06% |
| Shares Outstanding | 31.06M |
| Float | 7.38M |
Source: Nexqual, June 10, 2026 at 07:41 UTC.
Leadership (INBP)
Integrated Biopharma Inc is led by Riva Kay Sheppard (age 58), Co-CEO & Director, per Nexqual as of June 10, 2026 at 07:41 UTC.
| Co-CEO & Director | Riva Kay Sheppard (age 58) |
|---|---|
| Co-CEO & Director | Christina Kay (age 55) |
| Senior VP, CFO & Secretary | Dina L. Masi (age 64) |
From Integrated Biopharma Inc's Latest SEC 10-K Filing (filed 2025-09-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg.
- The company operates through two segments, Contract Manufacturing and Other Business Lines.
- The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
- The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EAWD | Energy and Water Development Co | USD 0.01 | ▲ 0% |
| BNKL | BIONIK LABORATORIES CORP | USD 0 | ▲ 0% |
| PACV | Pacific Ventures Group Inc. | USD 0 | ▲ 0% |
| CUAUF | C3 METALS INC. | USD 0.57 | ▲ 0% |
| ESHSF | EDDY SMART HOME SOLUTIONS LTD | USD 1 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:41 UTC. This page is informational and not investment advice.